Introduction: The continued use of PEG in patients with advanced dementia and feeding difficulties might be due to poor physician knowledge. The literature suggests that PEG feeding does not improve survival, pressure ulcers, weight, or aspiration risk in this group, and that 1-year mortality post-insertion is 50-70%. Our goal was to evaluate the knowledge of gastroenterology (GI) and general internal medicine (IM) physicians regarding the benefits of PEG in advanced dementia. Methods: The program directors of 58 GI fellowships and 30 IM residencies agreed to distribute an e-mail to all faculty/trainees within their respective academic divisions inviting them to complete a webbased survey. The anonymous survey inquired about the benefits of PEG in advanced dementia (survival, ulcer formation/healing, weight gain, aspiration risk). Respondents also self-assessed their knowledge of the relevant literature. Results: There were 670 respondents (135 GI attendings, 195 IM attendings, 95 GI fellows, 245 IM residents). More GI attendings (54%) felt well-versed in the literature about the outcomes of PEG in advanced dementia than IM attendings (34%; p<0.05) and residents (17%; p<0.05); there was no difference compared to GI fellows. There was significant difference in knowledge between those who felt well-versed in the literature to those who did not (Table 1). Misconception that PEG results in weight gain and ulcer healing was pronounced (Table 1). Knowledge of 1-year mortality rate post PEG insertion was poor (Table 2).Table 1: Physicians' Knowledge About the Benefits of PEG Feeding in Advanced Dementia*Table 2: Physicians’ Estimation of 1-Year Mortality Post Insertion of PEG in Advanced DementiaConclusion: Many physicians do not feel knowledgeable about the outcomes of PEG in advanced dementia. There is misconception about the benefits of PEG feeding and underestimation of mortality post-PEG. This deficiency of knowledge might contribute to PEG tubes being recommended for patients with advanced dementia. Disclosure - Dr. Colin Howden: Consultant: Takeda, Otsuka, Ironwood, Salix, Pfizer Consumer Health. Dr. Colin Howden: Speaking honoraria from Takeda, Otsuka, Ironwood, Forest, GlaxoSmithKline International. Dr. Alan Wong: none.